Tag: Hemangiosarcoma

Original Project Description:

Canine hemangiosarcoma is the most aggressive cancer seen in all dogs, but disproportionately affects older, large breed dogs. Despite aggressive treatment with surgery and chemotherapy, more than 50% of dogs die due to metastatic spread of their cancer within 6 months and no significant advancements in the treatment of hemangiosarcoma have occurred in over 30 years. Several challenges have hindered improvements in outcomes including limitations in the capabilities of current imaging and/or blood-based markers to detect early  relapse/metastasis, gaps in current understanding of the molecular biology of hemangiosarcoma, and a lack of effective therapies that effectively alter the aggressive metastatic behavior of this cancer. Continue reading “Research Update 02946-EY4: Towards Curative Outcomes in Canine Hemangiosarcoma” →

Original Project Description:

Canine hemangiosarcoma is the most aggressive cancer seen in all dogs, but disproportionately affects older, large breed dogs. Despite aggressive treatment with surgery and chemotherapy, more than 50% of dogs die due to metastatic spread of their cancer within 6 months and no significant advancements in the treatment of hemangiosarcoma have occurred in over 30 years. Several challenges have hindered improvements in outcomes including limitations in the capabilities of current imaging and/or blood-based markers to detect early  relapse/metastasis, gaps in current understanding of the molecular biology of hemangiosarcoma, and a lack of effective therapies that effectively alter the aggressive metastatic behavior of this cancer. Continue reading “Research Update 02946-MY4: Towards Curative Outcomes in Canine Hemangiosarcoma” →

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally  designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically  detrimental and life-threatening. The study has two objectives. The first is to determine the most  reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention.

To complete the first objective, we conducted surveys to determine the health status of every dog enrolled in Shine On phase-3 (SO3, the early detection phase) at 6-month intervals. Continue reading “Research Update CHF 02806-MOU FINAL: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up” →

We have completed enrollment for the trial. We are currently analyzing the pharmacokinetic data obtained from the blood samples of dogs enrolled in the study. The project goals have not been modified. Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Specifically: Objective 1: We will confirm the tolerability and estimate the clinical benefit of propranolol in combination with doxorubicin. Continue reading “Research Update CHF 02534 EY5 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma” →

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to  prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study  has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how  long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result  and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously  enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of  hemangiosarcoma, and to provide eBAT as a strategy for prevention in up to 12 of these dogs. Continue reading “Research Update CHF 02806-MOU EY4: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up” →

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention in up to 12 of these dogs. Continue reading “Research Update CHF 02806-MOU MY4: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up” →

We have completed enrollment for the trial. We are currently analyzing the pharmacokinetic data obtained from the blood samples of dogs enrolled in the study. The project goals have not been modified.

Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Specifically:

Objective 1: We will confirm the tolerability and estimate the clinical benefit of propranolol in combination with doxorubicin.

Objective 2: We will assess levels of propranolol in the bloodstream after long-term administration to dogs with hemangiosarcoma to determine if there is a correlation between drug levels in blood and overall survival. We will also determine if propranolol alters the blood levels (exposure) of doxorubicin in dogs receiving propranolol and compare these levels to those found in the published literature fordogs receiving doxorubicin. Collection of these data will allow us to better understand how these drugs may be working together. Continue reading “Research Update CHF 02534 MY5 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma” →